Abstract: Compositions and methods are provided for delayed breaking of viscoelastic surfactant gels inside subterranean formations. Breaking is accomplished without mechanical intervention or use of a second fluid. The delayed breaking agent is selected from alkyl ether phosphates and salts thereof, alkylaryl ether phosphates and salts thereof, alkyl sulfates and salts thereof, alkylaryl sulfates and salts thereof, alkyl ether sulfates and salts thereof, alkylaryl ether sulfates and salts thereof, and mixtures of any of the foregoing. The viscoelastic surfactant can be a zwitterionic surfactant, and can be selected from the group consisting of sultaines, betaines, and amidoamine oxides.

Abstract: Compositions and methods are provided for delayed breaking of viscoelastic surfactant gels inside subterranean formations. Breaking is accomplished without mechanical intervention or use of a second fluid. The delayed breaking agent is selected from alkyl ether phosphates and salts thereof, alkylaryl ether phosphates and salts thereof, alkyl sulfates and salts thereof, alkylaryl sulfates and salts thereof, alkyl ether sulfates and salts thereof, alkylaryl ether sulfates and salts thereof, and mixtures of any of the foregoing. The viscoelastic surfactant can be a zwitterionic surfactant, and can be selected from the group consisting of sultaines, betaines, and amidoamine oxides.

Abstract: This application is directed to the use of steroid compounds for the selective inhibition of the enzyme PTP1B in a mammal for the treatment of diabetes.

Abstract: This application is directed to the use of steroid compounds for the selective inhibition of the enzyme PTP1B in a mammal for the treatment of diabetes.

Abstract: Therapeutic peptides having guanylyl cyclase C agonist activity are disclosed. The therapeutic peptides are analogues of the E. coli STa peptide with non-natural amino acid, isosteric or D-amino acid substituents. The therapeutic peptides are useful in the treatment of chronic ideopathic constipation, inflammatory bowel disease, and other diseases. Pharmaceutical compositions comprising the therapeutic peptides are also disclosed.

Abstract: Therapeutic peptides having guanylyl cyclase C agonist activity are disclosed. The therapeutic peptides are analogues of the E. coli STa peptide with non-natural amino acid, isosteric or D-amino acid substituents. The therapeutic peptides are useful in the treatment of chronic ideopathic constipation, inflammatory bowel disease, and other diseases. Pharmaceutical compositions comprising the therapeutic peptides are also disclosed.

Abstract: Therapeutic peptides having guanylyl cyclase C agonist activity are disclosed. The therapeutic peptides are analogues of the E. coli STa peptide with non-natural amino acid, isosteric or D-amino acid substituents. The therapeutic peptides are useful in the treatment of chronic ideopathic constipation, inflammatory bowel disease, and other diseases. Pharmaceutical compositions comprising comprising the therapeutic peptides are also disclosed.

Abstract: Proliferation of colorectal, gastric and esophageal cancer cells is inhibited by administering ST receptor ligand. The number of ST receptor molecules on the surface of a colorectal cell or metastasized colorectal cancer cell are increased by administering an ST receptor ligand such that ligand comes into contact with an ST receptor on the surface of the colorectal cell. Pharmaceutical compositions comprise sterile, pyrogen free ST receptor ligand and a pharmaceutically acceptable carrier or diluent. Metastasized colorectal cancer is treated or imaged by increasing the number of ST receptor molecules on the surface of a metastasized colorectal cancer cell and then administering a pharmaceutical composition containing components that target the ST receptor for delivery of a therapeutic agent or imaging agent. Methods of detecting metastasized colorectal cancer are disclosed. Methods of delivering active compounds to a colorectal cell in an individual are disclosed.

Abstract: This application is directed to the use of steroid compounds for the selective inhibition of the enzyme PTP1B in a mammal for the treatment of diabetes.

Abstract: The present invention provides a method of purifying diphtheria toxin comprising (1) fermenting a microorganism strain capable of producing diphtheria toxin using glucose as a carbon source, said method comprising adding glucose to a growing culture whereby the addition of glucose maintains microorganism growth effective to support diphtheria toxin production; and (2) purifying the diphtheria toxin from the culture by contacting a toxin containing preparation derived therefrom with an ion exchange matrix, eluting a fraction containing the toxin, applying the eluate to a hydrophobic matrix, and eluting a fraction containing the toxin.

Abstract: Current methods for station keeping an object in the ocean or body of water involve mooring assemblies or active and complex navigation and differential thrust or thrust and rudder assemblies. The embodiments herein provide a method and device for compensating for the force of water or ocean currents through the use of a hydrofoil assembly to orient a device in the water current direction, through the use of any number of devices for sensing water current force, and through the use of a motor assembly to produce sufficient thrust to compensate for water current drift. An alternate embodiment allows the method to be employed without sensing the force of the water current. The method does not require directional thrust or active rudder assemblies, is highly portable, utilizes minimal power, is light weight, is scalable, and can be operated in any body of water.

Abstract: The present invention provides a method of purifying diphtheria toxin comprising (1) fermenting a microorganism strain capable of producing diphtheria toxin using glucose as a carbon source, said method comprising adding glucose to a growing culture whereby the addition of glucose maintains microorganism growth effective to support diphtheria toxin production; and (2) purifying the diphtheria toxin from the culture by contacting a toxin containing preparation derived therefrom with an ion exchange matrix, eluting a fraction containing the toxin, applying the eluate to a hydrophobic matrix, and eluting a fraction containing the toxin.

Abstract: A magnetic drive and mechanical oscillator system comprising a mechanical oscillator, a coil, a means for providing alternating current to said coil thereby creating a magnetic field within and about the coil, said means including an on-off means and a ferromagnetic material in communication with the diaphragm of the mechanical oscillator and the coil.

Abstract: The present invention is directed to the use of compound 1436 for the induction of weight loss in an obese mammal.

Abstract: The present invention provides a method of purifying diphtheria toxin comprising (1) fermenting a microorganism strain capable of producing diphtheria toxin using glucose as a carbon source, the method comprising adding glucose to a growing culture whereby the addition of glucose maintains microorganism growth effective to support diphtheria toxin production; and (2) purifying the diphtheria toxin from the culture by contacting a toxin containing preparation derived therefrom with an ion exchange matrix, eluting a fraction containing the toxin, applying the eluate to a hydrophobic matrix, and eluting a fraction containing the toxin.

Abstract: The present invention is a mechanical oscillator metal loss sensor for use in a corrosive or erosive environment. The elements include a means for mechanical excitation, and a mechanical oscillator with two regions that corrode differently, where the regions are determined to affect specific influences on the resonance parameters, wherein said mechanical oscillator has a resonant frequency, f, and a quality factor, Q. In a preferred embodiment, the mechanical oscillator has the shape of a tuning fork.

Abstract: A peptide-chelate with affinity for the ST receptor is disclosed, wherein the chelate is tetradentate. The peptide-chelate conjugate of the invention may be labelled with a radiometal to provide a metal complex. A radiopharmaccutical composition comprising the metal complex is provided, which is suitable for the diagnostic imaging of colorectal cancer. Also provided for in the invention is a kit for the preparation of the radiopharmaceutical preparation.

Abstract: The present invention provides a method of purifying diphtheria toxin comprising (1) fermenting a microorganism strain capable of producing diphtheria toxin using glucose as a carbon source, said method comprising adding glucose to a growing culture whereby the addition of glucose maintains microorganism growth effective to support diphtheria toxin production; and (2) purifying the diphtheria toxin from the culture by contacting a toxin containing preparation derived therefrom with an ion exchange matrix, eluting a fraction containing the toxin, applying the eluate to a hydrophobic matrix, and eluting a fraction containing the toxin.